Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ernest Nadal

Showing results (41-50 of 166) with videos related to

Pageof 17
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 11, 2025
Emerging Role of Targeted Therapies Combined With Radiotherapy in Inoperable Stages I to III NSCLC: A Review From the IASLC ART SubcommitteeSarah Bowen Jones, Clara Chan, Andrea R Filippi, et al.
Endocrine|February 27, 2019
Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomesInmaculada Peiró, Ramón Palmero, Pedro Iglesias, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 22, 2020
Starvation and antimetabolic therapy promote cytokine release and recruitment of immune cellsFranziska Püschel, Francesca Favaro, Jaime Redondo-Pedraza, et al.
Lung Cancer (Amsterdam, Netherlands)|March 1, 2011
Phase I study of concurrent chemoradiation with pemetrexed and cisplatin followed by consolidation pemetrexed for patients with unresectable stage III non-small cell lung cancerFelipe Cardenal, María Dolores Arnaiz, Teresa Morán, et al.
Cancers|December 17, 2024
Neoadjuvant Therapy in Robotic Lung Surgery: Elevating Surgical Complexity Without Compromising OutcomesInés Serratosa, Carlos Déniz, Camilo Moreno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2018
<i>MET</i>-Oncogenic and <i>JAK2</i>-Inactivating Alterations Are Independent Factors That Affect Regulation of PD-L1 Expression in Lung CancerMaria Saigi, Juan J Alburquerque-Bejar, Anne Mc Leer-Florin, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|April 25, 2018
Preoperative nutritional status assessment predicts postoperative outcomes in patients with surgically resected non-small cell lung cancerRicard Ramos, Ernest Nadal, Inma Peiró, et al.
Clinical Lung Cancer|November 30, 2016
Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Non-Small-Cell Lung CancerEdward B Garon, Martin Reck, Luis Paz-Ares, et al.
Therapeutic Advances in Medical Oncology|December 30, 2025
TROPION-Lung15: a randomized phase III study of osimertinib combined with datopotamab deruxtecan (Dato-DXd) or Dato-DXd alone versus platinum-doublet chemotherapy in patients with <i>EGFR</i>-mutated advanced non-small cell lung cancer and whose disease has progressed on prior osimertinibDaniel Shao-Weng Tan, Ernest Nadal, Parneet Cheema, et al.
Lung Cancer (Amsterdam, Netherlands)|August 9, 2023
Pembrolizumab as first-line treatment for advanced NSCLC in older adults: A phase II clinical trial evaluating geriatric and quality-of-life outcomesRemei Blanco, Manuel Dómine, José Luis González, et al.
Pageof 17

Showing results (41-50 of 166) with videos related to

Sort By:
Pageof 17
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 11, 2025
Emerging Role of Targeted Therapies Combined With Radiotherapy in Inoperable Stages I to III NSCLC: A Review From the IASLC ART SubcommitteeSarah Bowen Jones, Clara Chan, Andrea R Filippi, et al.
Endocrine|February 27, 2019
Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomesInmaculada Peiró, Ramón Palmero, Pedro Iglesias, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 22, 2020
Starvation and antimetabolic therapy promote cytokine release and recruitment of immune cellsFranziska Püschel, Francesca Favaro, Jaime Redondo-Pedraza, et al.
Lung Cancer (Amsterdam, Netherlands)|March 1, 2011
Phase I study of concurrent chemoradiation with pemetrexed and cisplatin followed by consolidation pemetrexed for patients with unresectable stage III non-small cell lung cancerFelipe Cardenal, María Dolores Arnaiz, Teresa Morán, et al.
Cancers|December 17, 2024
Neoadjuvant Therapy in Robotic Lung Surgery: Elevating Surgical Complexity Without Compromising OutcomesInés Serratosa, Carlos Déniz, Camilo Moreno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2018
<i>MET</i>-Oncogenic and <i>JAK2</i>-Inactivating Alterations Are Independent Factors That Affect Regulation of PD-L1 Expression in Lung CancerMaria Saigi, Juan J Alburquerque-Bejar, Anne Mc Leer-Florin, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|April 25, 2018
Preoperative nutritional status assessment predicts postoperative outcomes in patients with surgically resected non-small cell lung cancerRicard Ramos, Ernest Nadal, Inma Peiró, et al.
Clinical Lung Cancer|November 30, 2016
Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Non-Small-Cell Lung CancerEdward B Garon, Martin Reck, Luis Paz-Ares, et al.
Therapeutic Advances in Medical Oncology|December 30, 2025
TROPION-Lung15: a randomized phase III study of osimertinib combined with datopotamab deruxtecan (Dato-DXd) or Dato-DXd alone versus platinum-doublet chemotherapy in patients with <i>EGFR</i>-mutated advanced non-small cell lung cancer and whose disease has progressed on prior osimertinibDaniel Shao-Weng Tan, Ernest Nadal, Parneet Cheema, et al.
Lung Cancer (Amsterdam, Netherlands)|August 9, 2023
Pembrolizumab as first-line treatment for advanced NSCLC in older adults: A phase II clinical trial evaluating geriatric and quality-of-life outcomesRemei Blanco, Manuel Dómine, José Luis González, et al.
Pageof 17